Ventracor chalks up first revenues

By Ruth Beran
Tuesday, 20 September, 2005

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.

The company previously indicated it would reach the milestone before the end of 2005.

The University of Sydney formalises cervical cancer elimination partnership

The success of a cervical cancer elimination program has led to the signing of a memorandum of...

Noxopharm says paper reveals science behind its immune system platform

Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...

Neurosensing/neurostimulation implants session to be held on Monday

On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...

Content from other channels on our network

Community mistrust puts renewable energy rollout at risk

Aussie low-carbon concrete created using calcinated clay

10 lessons found to improve urban sustainability experiments

Liquid metal to 'harvest' clean hydrogen from water

Epson makes progress with sustainability plans and initiatives in Australia and New Zealand

Australian Vanadium partners with Sumitomo on Kalgoorlie battery bid

Open Process Automation: how and where to start

OT cyber adversaries increasing real-world impact: report

Five common mistakes in industrial temperature monitoring

NSW renewables workforce receives $15m government investment

Does cultured beef have fewer allergens?

Unlocking the benefits of avocados across the value chain

Risk management approach for toxin in infant formula

The Magnum Ice Cream Company partners with Seabin for wrapper clean-up

$15m AI space project to help boost Australian agriculture